Current advances in sustained-release systems for parenteral drug delivery

Expert Opinion on Drug Delivery

Volumn 2, Issue 6, 2005, Pages 1039-1058

  Shi, Yi ^a   Li, Luk Chiu ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Biodegradable polymer; Chemical conjugation; Implant; In situ gelling system; Lipid microparticle; Liposome; Micro and nanoparticulate systems

Indexed keywords

ABARELIX; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; DRUG CARRIER; HISTRELIN; HUMAN GROWTH HORMONE; IMPANON; INSULIN; LEUPRORELIN; LEVONORGESTREL; LOCAL ANESTHETIC AGENT; MACROGOL; MORPHINE SULFATE; NANOPARTICLE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OCTREOTIDE; PACLITAXEL; PEG INTRO; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; POLY(ORTHO ESTER); POLYANHYDRIDE; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; PROTEIN DERIVATIVE; RISPERIDONE; TRIPTORELIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACROMEGALY; ADVANCED CANCER; ANEMIA; BIODEGRADATION; CROSS LINKING; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG MARKETING; ENCAPSULATION; HEPATITIS C; HUMAN; OVARY CANCER; POSTOPERATIVE PAIN; PROSTATE CANCER; REVIEW; SCHIZOPHRENIA; SUSTAINED RELEASE FORMULATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; GELS; GLYCOLATES; HUMANS; INJECTIONS; LIPOSOMES; MICROSPHERES; NANOSTRUCTURES; POLYANHYDRIDES; POLYESTERS; POLYMERS; PROTEINS;

EID: 28244434064     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.6.1039     Document Type: Review

References (144)

1. GABIZON A: Selective tumor localization and improved therapeutic index of anthracylines encapsulated in long-circulating liposomes. Cancer Res. (1992) 52(4):891-896.
2. FLEMING AB, SALTZMAN WM: Pharmacokinetics of die carmustine implant. Clin. Pharmacokinet. (2002) 41(6):403-419.
3. LI LC, DENG J, STEPHENS D: Polyanhydride implant for antibiotic delivery-from the bench to the clinic. Adv. Drug Del. Rev. (2002) 54:963-986.
4. GUPTE A, CIFTCI K: Formulation and characterization of paclitaxel, 5-FU and paclitaxel +5-FU microspheres. Int. J. Pharm. (2004) 276:93-106.
5. LAGARCE F, RENAUD P, FAISANT N et al.: Baclofen-loaded microspheres: preparation and efficacy testing in a new rabbit model. Eur. J. Pharm. Biapharm. (2005) 59:449-459.
6. NARAHARISETTI PK, LEW MD, FU Y-C, LEE D-J, WANG C-H: Gentamicin-loaded discs and microspheres and their modifications: characterization and in vitro release. J. Control. Release (2005) 102:345-359.
7. CUI F, CUN D, TAO A et al.: Preparation and characterization of melittin-loaded poly-(D,L-lactic acid) of poly(D,L-lactic-co-glycolic acid) microspheres made by the double emulsion method. J. Control. Release (2005) (In press).
8. KOSTANSKI JW, DANI BA, REYNOLDS GA, BOWERS CY, DELUCA PP: Evaluation of orntide microspheres in a rat animal model and correlation to in vitro release profiles. AAPS Pharm. Sci. Tech. (2000) 1(4):E27.
9. BLANCO-PRIETO MJ, CAMPANERO MA, BESSEGHIR K, HEIMGATNER F, GANDER B: Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres. J. Control. Release (2004) 96:437-448.
10. JIANG W, GUPTA RK, DESHPANDE MC, SCHWENDEMAN SP: Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Del. Rev. (2005) 57:391-410.
11. SINHA VR, TREHAN A: Biodegradable microspheres for protein delivery. J. Control. Release (2003) 90:261-280.
12. RADULESCU D, SCHWADE N, WAWRO D: Uniform paclitaxel-loaded biodegradable micropsheres manufactured by ink-jet technology. Proceedings of the Winter Symposium and 11th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT, USA (2003).
13. CLELAND JL, JOHNSON OL, PUTNEY S, JONES AJ: Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development. Adv. Drug Del. Rev. (1997) 28:71-84.
14. YEO Y, PARK K: A new microencapsulation method using an ultrasonic atomizer based on interfacial solvent exchange. J. Control. Release (2004) 100(3):379-388.
15. ELVASSORE A, BERTUCCO A, CALICETI P: Production of insulin-loaded poly(ethylene glycol)/poly(lactide) (PEG/PLA) nanoparticles by gas antisolvent techniques. J. Pharm. Sci. (2001) 90(10):1628-1636.
16. 2 in a mixed solvent. Ind. Eng. Chem. Res. (2001) 40:795-800.
17. WHITAKER MJ, HAO J, DAVIES OR et al.: The production of protein-loaded microparticles by supercritical fluid enhanced mixing and spraying. J. Control. Release (2005) 101(1-3):85-92.
18. HOWDLE SM, WATSON MS, WHITAKER MJ et al.: Supercritical fluid mixing: preparation of thermally sensitive polymer composites containing bioactive materials. Chem. Comm. (2001) 1:109-110.
19. KISSEL T, LI YX, VOLLAND C, GÖRICH S, KONEBERG R: Parenteral protein delivery systems using biodegradable polyesters of ABA block structure, containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethylene oxide) B blocks. J. Control. Release (1996) 39(2-3):315-326.
20. RONNEBERGER B, KISSEL T, ANDERSON JM: Biocompatibility of ABA triblock copolymer microparticles consisting of poly(L-lactic-co-glycolic-acid) A-blocks attached to central poly(oxyethylene) B-blocks in rats after intramuscular injection. Eur. J. Pharma. Biopharm. (1997) 43(1):19-28.
21. MORLOCK M, KISSEL T, LI YX, KOLL H, WINTER G: Erythropoietin loaded microspheres prepared from biodegradable LPLG-PEO-LPLG triblock copolymers: protein stabilization and in vitro release properties. J. Control. Release (1998) 56(1-3):105-115.
22. BREITENBACH A, LI YX, KISSEL T: Branched biodegradable polyesters for parenteral drug delivery systems. J. Control. Release (2000) 64(1-3):167-178.
23. LI Y, NOTHNAGEL J, KISSEL T: Biodegradable brush-like graft polymers from poly(D, L-lactide) or poly(D, L-lactide-co-glycolide) and charge-modified, hydrophilic dextrans as backbone-synthesis, characterization and in vitro degradation properties. Polymer (1997) 38(25):6197-6206.
24. BELETSI A, PANAGI Z, AVGOUSTAKIS K: Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int. J. Pharm. (2065) 298(1):233-241.
25. SINHA VR, AGGARWAL A, TREHAN A: Biodegradable PEGylated microspheres and nanospheres. Am. J. Drug Deliv. (2005) 2(3):157-171.
26. SINHA VR, BANSAL K, KAUSHIK R, KUMRIA R, TREHAN A: Poly-E-caprolactone microspheres and nanospheres: an overview. Int. J. Pharm. (2004) 278:1-23.
27. SHENOY DB, D'SOUZA RJ, TIWARI SB, UDUPA N: Potential applications of polymeric microsphere suspension as subcutaneous depot for insulin. Drug Dev. Ind. Pharm. (2003) 29(5):555-563.
28. MARTIN LG, COLLETT JH, ATTWOOD D: The release of 5-fluorouracil from microspheres for poly(E-caprolactone-co-ethylene oxide). Drug Dev. Ind. Pharm. (2000) 26(1)7-12.
29. ZHOU S, DENG X, YANG H: Biodegrdable poly(E-caprolactone)-poly(ethylene glycol) block copolymers: characterization and their use as drug carriers for a controlled delivery system. Biomaterials (2003) 24:3563-3570.
30. DONG C-M, GUO Y-Z, QIU K-Y, GU Z-W, FENG X-D: In vitro degradation and controlled release behavior of D, L-PLGA50 and PCL-b-D,L-PLGA50 copolymer microspheres. J. Control. Release (2005) 107:53-64.
31. HARPER E, DANG W, LAPIDUS RG, ROBERT I, GARVER J: Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin. Cancer Res. (1999) 5:4242-4248.
32. XU X, YU H, GAO S et al.: Polyphosphoester microspheres for sustained release of biologically active nerve growth factor. Biomaterials (2002) 23(17):3765-3772.
33. WANG J, MAO H-Q, LEONG KW: A novel biodegradable gene carrier based on polyphosphoester. J. Am. Chem. Soc. (2001) 123:9480-9481.
34. LI KW, DANG W, TYLER BM et al.: Polilactofate microspheres for paclitaxel delivery to central nervous system malignancies. Clin. Cancer Res. (2003) 9:3441-3447.
35. KUMAR N, LANGER RS, DOMB AJ: Polyanhydrides: an overview. Adv. Drug Del. Rev. (2002) 54:889-910.
36. JAIN JP, MODI S, DOMB AJ, KUMAR N: Role of polyanhydrides as localized drug carrier. J. Control. Release (2005) 103:541-563.
37. HELLER J, BARR J: Biochronomer technology. Expert Opin. Drug Delivery (2005) 2(1):169-183.
38. NG SY, SHEN HR, LOPEZ E et al.: Development of a poly(ortho ester) prototype with a latent acid in the polymer backbone for 5-fluorouracil delivery. J. Control. Release (2000) 65:367-374.
39. ROTHEN-WEINHOLD A, SCHWACH-ABDELLAOUI K, BARR J et al.: Release of BSA from poly(ortho ester) extruded thin strands. J. Control. Release (2001) 71:31-37.
40. DENG J-S, LI L, TIAN Y et al.: In vitro characterization of polyorthoester microparticles containing bupivacaine. Pharm. Develop. Technol. (2003) 8(1):31-38.
41. BAI X-L, YANG Y-Y, CHUNG T-S, NG S, HELLER J: Effect of polymer compositions on the fabrication of poly(ortho-ester) microspheres for controlled release of protein. J. Appli. Polymer Sci (2001) 80(10):1630-1642.
42. FOURNIER E, PASSIRANI C, COLIN N et al.: Development of novel 5-FU-loaded poly(methylidene malonate 2.1.2)-based microspheres for the treatment of brain cancers. Eur. J. Pharm. Biopharm. (2004) 57(2):189-197.
43. YANG Y-Y, WAN J-P, CHUNG T-S et al.: POE-PEG-POE triblock copolymeric microspheres containing protein: I. Preparation and characterization. J. Control. Release (2001) 75(1-2):115-128.
44. DESCHAMPS AA, GRIJPMA DW, GEIJEN J: Poly(ethylene oxide)/poly(butylenes teraphthalate) segmented block copolymers: the effect of copolymer composition on physical properties and degradation behavior. Polymer (2001) 42:9335-9345.
45. DESCHAMPS AA, APELDOORN AA, HAYEN H et al.: In vivo and in vitro degradation of poly(ether ester) block copolymers based on poly(ethylene glycol) and poly(butylene terephthalate). Biomaterials (2004) 25(2):247-258.
46. JANSEN JA, RUIJTER JE, JANSSEN PT, PAQUAY YG: Histological evaluation of a biodegradable polyactive®/hydroxyapatite membrane. Biomaterials (1995) 16(11):819-827.
47. BEZEMER JM, RADERSMA R, GRIJPMA DW et al.: Microspheres for protein delivery prepared from amphiphilic multiblock copolymers 2. Modulation of release rate. J. Control. Release (2000) 67:249-260.
48. FRANSSEN O, VENDERVENNET L, RODERS P, HENNINK WE: Degradable dextran hydrogels: controlled release of a model protein from cylinders and microspheres. J. Control. Release (1999) 60:211-221.
49. STENEKES RJH, FRANSSENO O, BOMMEL WM, CROMMELIN DJ, HENNINK WE: The use of aqueous PEG/dextran phase separation for the preparation of dextran microspheres. Int. J. Pharm. (1999) 183:29-32.
50. CHUNG JT, VLUGT-WENSINK KDF HENNINK WE, ZHANG Z: Effect of polymerization conditions on the network properties of dex-HEMA microspheres and macro-hydrogels. Int. J. Pharm. (2005) 288:51-61.
51. STENEKES RJ, HENNINK WE: Equilibrium water content of microspheres based on cross-linked dextran. Int. J. Pharm. (1999) 189:131-135.
52. CADEE JA, DEGROOT CJ, JISKOOT W, OTTER WD, HENNINK WE: Release of recombinant human interleukin-2 from dextran-based hydrogels. J. Control. Release (2002) 778:1-13.
53. KOTEN JW, LUYN MJ, CADEE JA et al.: IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. Cytokine (2003) 24:57-66.
54. DE GROOT CJ, VAN LUYN MJ, VAN DIJK-WOLTHUIS WN et al.: In vitro biocompatibility of biodegradable dextran-based hydrogels tested with human fibroblasts. Biomaterials (2001) 22(11):1197-1203.
55. CONSTANCIS A, MEYRUEIX R, BRYSON N et al.: Macromolecular colloids of diblock poly(amino acids) that bind insulin. J. Colloid Interface Sci. (1999) 217(2):357-368.
56. KOCH M, STEIDLE C, BROSMAN S et al.: An open-label study of abarelix in men with sympotomatic prostate cancer at risk of treatment with LHRH agonist. Urology (2003) 62 (5):877-882.
57. KNIGHTH CG: Liposomes: From Physical Structure To Therapeutic Application. Elsevier/North Holland Biomedical Press, New York, NY, USA (1981):381-390.
58. MAEDA H, SAWA T, KONNO T: Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release (2001) 74:47-61.
59. STROM G, OUSSOREN C, PEETERS P, BARNHOLZ Y: Tolerabillity of liposomes in vivo. In: Liposome Technology. G Gregoriadis (Ed.), CRC Press, Boca Raton, FL, USA (1993):345-383.
60. WOODLE M: Controlling liposome blood clearances by surface-grafted polymers. Adv. Drug Del. Rev. (1998) 32:139-152.
61. CEH B, WINTERHALTER M, FREDERIK PM, VALLNER JJ, LASCI DD: Stealth liposomes: from theory to product. Adv. Drug Del. Rev. (1997) 24:165-177.
62. IMMORDINAO ML, BRUSA P, ARPICCO S et al.: Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Control. Release (2003) 91:417-429.
63. SETHI V, ONYUKSEL H, RUBINSTEIN I: Liposomal vasoactive interstinal peptide. Meth. Enzym. (2005) 391:377-395.
64. HAGEN TL: Lipsomal cytokines in the treatment of infectious diseases and cancer. Meth. Enzym. (2005) 391:125-145.
65. SLOOTEN ML, BOERMAN O, ROMOREN K et al.: Liposomes as sustained release system for human interferon-γ: biopharmaceutical aspect. Bioch. Biophys. ACTA (2001) 1530:134-145.
66. FELNEROVA D, VIRET JF, GLUCK R, MOSER C: Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotech. (2004) 15:518-529.
67. OKU N, NAMBA Y: Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents. Meth. Enzymol. (2005) 391:145-162.
68. ALLEN TM: Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer (2002) 2:750-764.
69. FORSSEN E, WILLIS M: Ligand-targeted liposomes. Adv. Drug Del. Rev. (1998) 29:249-271.
70. ZHANG JA, ANYARAMBHATLA G, MA L et al.: Development and charaterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur. J. Pharm. Biopharm. (2005) 59(1):177-187.
71. ZHANG JA, XUAN T, PARMAR M et al.: Development and charaterization of a novel liposome-based formulation of SN-38. Int. J. Pharm. (2004) 270(1-2):93-107.
72. WATERHOUSE DN, MADDEN TD, CULLIS PR, et al.: Preparation, characterization and biological analysis of liposomal formulation of vincristine. Meth. Enzym. (2005) 391:40-57.
73. OUSSORE C, STORM G, CROMMELIN DJ, SENIOR JH: In: Liposomes for local sustained drug release (Chapter 7). J Senior et al. (Eds), Interpharm/CRC, Press, Boca Raton, FL, USA (2000):
74. MANTRIPRAGADA S: A lipid based depot (DepoFoam® technology) for sustained release drug delivery. Prog. Lipid Res. (2002) 41(5):392-406.
75. YE Q, ASHERMAN J, STEVENSON M, BROWNSON E, KATRE NV: DepoFoam™ technology: a vehicle for controlled delivery of protein and peptide drugs. J. Control. Release (2000) 64(1-3):155-166.
76. WESTESE K, BUNJAS H, KOCH MH: Physicochemical characterization of lipid manoparticles and evaluation of their drug loading capacity and sustained release potential. J. Control. Release (1997) 48:223-236.
77. DELCURTO MD, CHICCO D, D'ANTONIO M et al.: Lipid microparticles as sustained release system for a GnRH antagonist (Antide). J. Control. Release (2003) 89(2):297-310.
78. LI LC, ZHU L, SONG JF et al.: Effect of solid state transition on the physical stability of suspensions containing bupivacaine lipid microparticles. Pharm. Dev. Tech (2005) 10:309-318.
79. SCHOLER N, KRAUSE K, KAYSER O et al.: Atovaquone nanosuspensions slow excellent therapeutic effect in a new murin model of reactivated toxoplamosis. Atntimicrob. Agents. Chemother. (2001) 45:1771-1779.
80. REITHMEIER H, HERRMANN J, GÖPFERICH A: Development and characterization of lipid microparticles as a drug carrier for somatostatin. Int. J. Pharm. (2001) 218(1-2):133-143.
81. REITHMEIER H, HERRMANN J, GÖPFERICH A: Lipid microparticles as a parenteral controlled release device for peptides. J. Control. Release (2001) 73(2-3):339-350.
82. ENGWICHT A, GIRRESER U, MÜLLER BW: Characterization of co-polymers of lactic and glycolic acid for supercritical fluid processing. Biomaterials (2000) 21(15):1587-1593.
83. SANTOS IR, RICHARD J, PECH B, THIES C, BENOIT JP: Microencapsulation of protein particles within lipids using a novel supercritical fluid process. Int. J. Pharm. (2002) 242(1-2):69-78.
84. TOONGSUWAN S, LI LC, ERICKSON BK, CHANG HC: Formulation and characterization of bupivacaine lipospheres. Int. J. Pharm. (2004) 28(1-2):57-65.
85. PAPAHADJOPOULOS D, VAIL WJ, JACOBSON K, POST G: Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim. Biophys. Acta. (1975) 394:483-491.
86. ZARIF L: Drug delivery by lipid cochleates. Meth. Enzym. (2005) 391:314-329.
87. ZARIF L, MANNINO RJ: Cochleates. In: Cancer Gene Therapy: Past Achievement and Future Challenge. N Habib (Ed.), Kluwer Academic/Plenum, New York, NY, USA (2000):83-94.
88. ZARIF L, PERLIN D: Amphotericin B nonocholeates: from formulation to oral efficacy. Drug Deliv. Tech. (2002) 2(4)
89. SEGARRA I, MOVSHIN DA, ZARIF L: Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system. J. Pharm. Sci. (2002) 91(8):1827-1837.
90. BRACHO G, LASTRE M, CAMPO JD et al.: Proteoliposome derived cochleate as novel adjuvant. Vaccine (2005) (In press).
91. GOULD-FOGERITE S, KHEIRI M, ZHANG F, MANNINO RJ: Cochleate delivery vehicles: applications in vaccine delivery. J. Liposome Res. (2001) 10:339-356.
92. GOULD-FOGERITE S, MANNINO RJ: Cochleate delivery vehicles: applications to gene therapy. Drug Del. Tech. (2003) 3(2)
93. PACKHAEUSER C, SCHNIEDERS J, OSTER CG, KISSEL T: in situ forming parenteral drug delivery systems: an overview. Eur. J. Pharm. Biopharm. (2004) 58:445-455.
94. MARTINI A, LAURIA S: Sustained release injectable products. Am. Pharm. Rev. (2003) 6(3):16-20.
95. TIPTON AI, DUNN RL: In situ gelling systems. In: Sustained-Release Injectable Products. JH Senior et al. (Eds), Interpharm Press, Boca Rota, FL, USA (2000):241-278.
96. SARTOR O: Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology (2003) 61(2 Suppl. 1):25-31.
97. OKUMU FW, DAO LN, FIELDER PJ et al.: Sustained delivery of human growth hormone from a novel gel system: SABER™. Biomaterials (2002) 23(22):4353-4358.
98. ZENTNER GM, RATHI R, SHIH C et al.: Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J. Control. Release (2001) 72:203-215.
99. MASAKI T, RATHI R, ZENTNER G et al.: Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int. (2004) 66(5):2061-2069.
100. CHOI S, KIM SW: Controlled release of insulin from injectable biodegradable triblock copolymer depot in ZDF rats. Pharm. Res. (2003) 20:2008-2010.
101. CHENITE A, CHAPUT C, WANG D et al.: Novel injectable neutral solutions of chitosan form biodegradable gets in situ. Biomaterials (2000) 21(21):2155-2161.
102. BERRADA M, SERREQI A, DABBARH F et al.: A novel non-toxic camptothecin formulation for cancer chemotherapy. Biomaterials (2005) 26(14):2115-2120.
103. YONG CS, CHOI JS, QUAN QZ et al.: Effect of sodium chloride on the gelation temperature, gel strength and bioadhesive forces of poloxamer gels containing diclofenac sodium. Int. J. Pharm. (2001) 226(1-2):195-205.
104. WASAN KM, SUBRANMANIAN R, KWONG M et al.: Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats. J. Pharmacol. Pharm. Sci. (2003) 6(2):189-197.
105. QIU Q, STEFANOS S, MA J et al.: A hydrogel prepared by in situ cross-linking of a thiol-containing poly(ethylene glycol)-based copolymer: a new biomaterial for protein drug delivery. Biomaterials (2002) 24(1):11-18.
106. OSTER CG, WITTMAR M, UNGER F et al.: Design of Amin-modified graft polyesters for effective gene delivery using DNA-loaded nanoparticles. Pharm. Res. (2004) 21(6):927-931.
107. PACKHAUSER C, WITTMAR M, KISSEL T: Novel in situ forming implants for bioactive macromolecules based on positively charged nanoparticles: preparation of insulin-loaded nanoparticles, characterization of depots and investigation of insulin release. CRS Annual Meeting. Miami, FL, USA (2005).
108. HELLER J, BARR J, NG S, SHEN HR: Injectable semi-solid poly(ortho esters) for the controlled delivery of therapeutic agents: synthesis and applications. Drug Del. Technol. (2002) 2(1)
109. DOMB AJ, ISRAEL ZH, ELMALAK O: Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors. Pharm. Res. (1999) 16(5):762-765.
110. ALLABABIDI S, SHAH JC: Efficacy and pharmacokinetics of site-specific cefazolin delivery using biodegradable implants in the prevention of post-operative wound infections. Pharm. Res. (1998) 15(2):325-333.
111. CHILUKURI DM, SHAH JC: Local delivery of vancomycin for the prophylaxis of prosthetic device-related infections. Pharm. Res. (2005) 22(4):563-572.
112. CROXATTO HB: Progestin implants. Steroids (2000) 65:681-685.
113. COSTANTINI LC, KLEPPNER SR, MCDONOUGH J, AZAR MR, PATEL R: Implantable technology for long-term delivery of nalmefene for treatment of alcoholism. Int. J. Pharm. (2004) 283:35-44.
114. WRIGHT JC, CHESTER AE, SKOWRONSKI RJ, LUCAS C: Long term controlled delivery of therapeutic agents via an implantable osmotically driven system: the DUROS implant. In: Modified-Release Drug Delivery Technology. MJ Rathbone et al. (Eds), Marcel Dekker, New York, NY, USA (2003):657-669.
115. WRIGHT JC, LEONARD ST, STEVENSON CL et al.: An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J. Control. Release (2001) 75(1-2):1-10.
116. WRIGHT JC, JOHNSON RM, YUM SL: DUROS osmotic pharmaceutical systems for parenteral and site directed therapy. Drug Del. Technol. (2003) 3(1).
117. DEHNAD H, BERRY S, FEREIRA P et al.: Functionality of osmotically driven, implantable therapeutic systems (DUROS implant): effects of osmotic pressure and delivery of suspension formulations of peptides and proteins. Proc. Int. Symp. Control. Rel. Bioact. Mater. (2000) 27:1016-1017.
118. FOWLER JE, GOTTESMAN JE, REID CF, ANDRIOLE GL, SOLOWAY M: Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J. Urology (2000) 164:730-734.
119. REYNOLDS L, RAUCK R, WEBSTER L et al.: Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain. Pain (2004) 110(1-2):182-188.
120. CHERTIN B, SPITZ IM, LINDENBERG T et al.: An implant releasing the gonadotropin hormone-releasing hormonte agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. J. Urology (2000) 163(3):838-844.
121. GREENWALD RB: Effective drug delivery by pegylated drug conjugates. Adv. Drug Del. Rev. (2003) 55:217-250.
122. JAIN S, HRECZU-HIRST DH, MCCORMACK B et al.: Polysialylated insulin: synthesis, characterization and biological activity in vivo. Biochim. Biophys. Acta (2003) 1622:42-49.
123. CALICETI P, VERONESE FM: Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Del. Rev. (2003) 55:1261-1277.
124. TSUNODA S, ISHIKAWA T, YAMAMOTO Y et al.: Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-α: a novel polymer-conjugation technique with a reversible amino-protective reagent. J. Pharmacol. Exp. Ther. (1999) 290:368-372.
125. TSUNODA S, ISHIKAWA T, WATANABE M et al.: Selective enhancement of thrombopoietic activity of PEGylated interleukin 6 by a simple procedure using a reversible aminoprotective reagent. Br. J. Haematology (2001) 112(1):181.
126. KOZLOWSKI A, HARRIS MJ: Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J. Control. Release (2001) 72(1-3):217-224.
127. MALIK F, BREW J, MAIDMENT SA, DELGADO C, FRANCIS GE: Peg-modified erythropoietin with improved efficacy. Exp. Hematology (2000) 28(7):106.
128. ESPOSITO P, BARBERO L, CACCIA P et al.: PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv. Drug Del. Rev. (2003) 55(10):1279-1291.
129. LEE LS, CONOVER C, SHI C, WHITLOW M, FILPULA D: Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug. Chem. (1999) 10:973-981.
130. VERONESE FM: Peptide and protein PEGylation: a review of problems and solutions. Biomaterials (2001) 22:405-417.
131. GREENWALD RB: PEG drugs: an overview. J. Control. Release (2001) 74:159-171.
132. MOREADITH RW, COLLEN D: Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction. Adv. Drug Del. Rev. (2003) 55:1337-1345.
133. GREGORIADIS G, JAIN S, PAPAIOANNOU I, LAING P: Improving the therapeutic efficacy of peptides and proteins: A role for polysialic acids. Int. J. Pharm. (2005) 300:125-130.
134. GREGORIADIS G, MCCORMACK B, WANG Z, LIFELY R: Polysialic acids: potential in drug delivery. FEBS Lett. (1993) 315:271-276.
135. FERNANDES AI, GREGORIADIS G: The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implications in its pharmacokinetics. Int. J. Pharm. (2001) 217:215-224.
136. JAIN S, HRECZUK-HIRST DH, MCCORMACK B et al.: Polysialylated insulin: synthesis, characterization and biological activiry in vivo. Biochim. Biophys. Acta (2003) 1622:42-49.
137. EPENETOS A, HRECZUK-HIRST DH, MCCORMACK B, GREGORIADIS G: Polysialylated proteins: a potential role in cancer therapy. Clin. Pharm. (2002) 21:2186.
138. KIM J-G, BAGGIO L, BRIDON D et al.: Development and characterization of a glucagon-like peptide 1-albumin conjugate-the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes (2003) 52:751-759.
139. LAWRENCE B, DREYFUS JF, WEN S et al.: CJC-1131, a long -acting GLP-1 derivative, exhibits an extended pharmacokinetic profile in healthy human volunteers. Annual ADA meeting. San Francisco, CA, USA (2003).
140. HRECZUK-HIRST D, CHICCO D, GERMAN L, DUNCAN R: Dextrins as potential carriers for drug targeting: tailored rates of dextrin degradation by introduction of pendant groups. Int. J. Pharm. (2001) 230(1-2):57-66.
141. DOMB AJ, LANGER R: Poly(anhydrides). 3. Poly(anhydrides) based on aliphatic-aromatic diacids. Macromolecules (1989) 22:3200-3204.
142. HELLER J, BARR J, NG SY, ABDELLAUOI KS, GURNY R: Poly(ortho esters): synthesis, characterization, properties and uses. Adv. Drug Del. Rev. (2002) 54:1015-1039.
143. KELLOMÄKI M, PAASIMAA S, GRIJPMA DW, KOLPPO K, TÖRMÄLÄ P: In vitro degradation of Polyactive® 1000PEOT70PBT30 devices. Biomaterials (2002) 23:283-295.
144. ZARIF L: Elongated supramolecular assemblies in drug delivery. J. Control. Release (2002) 81:7-23.